Previous studies have reported that progression-free survival in advanced HER2-negative breast cancer is improved by combined treatment with docetaxel and bevacizumab [17,35], the latter of which is a well-known antibody that inhibits interactions between VEGF ligands and their receptors [16]. The gene discussed is ERBB2; the disease is breast carcinoma.